title: A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
authors.forename: Catherine
authors.initials: C
authors.lastname: Roche-Lestienne
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Laï
authors.forename: Stéphane
authors.initials: S
authors.lastname: Darré
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
authors.forename: Claude
authors.initials: C
authors.lastname: Preudhomme
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D017354:Point Mutation; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases